Tracer library / [131I]ICF01012

[131I]ICF01012

Also written as [I-131]ICF01012
Radionuclide
I-131 t½ 11549 min
Modality
Therapy
Production route
—
Stage
Clinical research
Syntheses indexed
0
Melanoma

What it is

Compound class
Benzamide-based melanin-targeting radioligand
Target / mechanism
Binds melanin in pigmented melanoma cells PMID 31421458
Clinical application
Targeted radionuclide therapy for metastatic pigmented melanoma PMID 35428211
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
    2022 · BMC Cancer · Clinical study · Phase I

Need this precursor?We can point you to suppliers for [131I]ICF01012, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 35428211: 'This study is a first-in-human trial evaluating the [131I]ICF01012 TRT in metastatic malignant melanomas'. | Stage 30 (2026-09-18): Stage was 'phase I clinical trial (first-in-human)'; normalised to 'Clinical research', original wording kept here.
Ask a question